Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
09/23 JOHNSON & JOHNSON : Sen. Sparks to represent pharmaceutical companies in class a..
09/22 JOHNSON & JOHNSON : to occupy portion of Wexford innovation center
09/22 JOHNSON & JOHNSON : Research Shows That Canadian Military Servicemembers, First ..
09/22 JOHNSON & JOHNSON : Leaders Make Fortune's 2017 Most Powerful Women List
09/21 HEPATITIS C : Another "Child" of the Drug Industry, Says Ohio's Yes on Issue 2 C..
09/21 JOHNSON & JOHNSON : Research Shows That Canadian Military Servicemembers and Fir..
09/21 PFIZER : Goes to Court to Allow Competition for Biologics, Expand Options for Pa..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
09/21 SELL JOHNSON & JOHNSON BECAUSE OF IT : Goldman
09/21 PFIZER : sues J&J for violating US antitrust laws
More news
News from SeekingAlpha
09/23 Where To Invest Now
09/22 FDA rejects J&J's marketing application for RA med sirukumab, more safety dat..
09/22 REDHILL BIOPHARMA : Highly De-Risked And Undervalued With A Deep Pipeline
09/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 22, 2017
09/22 Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions
Financials ($)
Sales 2017 75 839 M
EBIT 2017 22 814 M
Net income 2017 16 690 M
Debt 2017 16 470 M
Yield 2017 2,55%
P/E ratio 2017 21,42
P/E ratio 2018 17,79
EV / Sales 2017 4,87x
EV / Sales 2018 4,51x
Capitalization 353 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 137 $
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633
SANOFI9.39%126 921